🔗 Share this article

While the United States undertakes unprecedented changes to its vaccine schedules, an unexpected name has emerged in a surprising turn: Høeg, a Danish American sports physician and epidemiologist who rose to prominence by expressing skepticism about Covid vaccines in the pandemic and has focused upon potential fatalities after Covid vaccination in her short position at the FDA.

Scheduled Shifts to Pediatric Vaccine Program

Agency leaders planned to unveil major revisions to the pediatric vaccination calendar earlier this month, bringing the US with the Danish vaccine program, sources say – a substantial departure that would place the US out of alignment with many the world with no evidence for improved outcomes. The announcement has been delayed until the new year.

Instead of the director of the vaccine center, Høeg is scheduled to present at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth person to head the center this year.

A Shift at the Regulatory Body

Høeg's temporary position could signify a strengthened alliance between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon rolling back previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing some childhood vaccine recommendations in the US in order to be more in line with the Danish model, a country with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccines – typically the responsibility of Dr. Prasad, director of the FDA’s vaccine center – as opposed to drug regulation.

Questions Over Expertise

The appointee has little discernible experience in pharmaceutical research, approval processes or management, which has been customary for former heads of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and the vaccine center since March.

“She appears not to have the necessary background” for overseeing the CDER, remarked Jonathan Howard. “She lacks experience running a scientific study. She has no expertise in leading a major agency. She has no expertise in drug approvals.”

Former heads of the center would “be deeply familiar with regulatory frameworks and the research of pharmaceutical innovation”, noted a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that previous people who ran the center have had.”

The drug center has an immense range of responsibilities at the FDA, Woodcock pointed out.

“The public just zeroes in on the novel medication approvals, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and other areas, and every single one must be managed,” Woodcock said. “The area you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative aspect to the role, which manages in excess of 5,000 personnel. “It is a huge leadership role, if you perform it correctly,” the former official said.

Official Statement and Contentious Programs

In response to inquiries about Høeg’s credentials and whether this assignment represents greater collaboration among agency officials on vaccines, a spokesperson stated that the “concerns stem from incorrect assumptions”.

“Her experience is consistent with the duties of her role,” the official said, pointing to the time Dr. Høeg spent counseling the agency head on “medication safety and regulatory science, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg takes over the commissioner’s recently launched fast-track approval initiative, a controversial expedited medication authorization process that allegedly troubled her predecessors. “By what process are these medications being chosen for this fast-track system? Who takes the choices?” Dr. Howard asked. “There is a lot of confidentiality occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards more relaxed oversight of most medications, with the exception of shots.”

Established Track Record on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if concerning, track record, critics observe. She authored a analysis using unconfirmed volunteer-provided data to assess the rate of myocarditis following COVID-19 vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccinations are more dangerous than they are.

Included in her “policy goals” for the incoming government encompassed revising rules for recently developed shots and halting “non-essential” vaccines, she stated post-election on a audio program. At the FDA, Høeg has according to sources floated the idea of excluding adolescent males from getting Covid vaccines.

“She’s an all-around ideologue who commences with her beliefs and works backwards to fit the data in a very deceptive, untruthful manner,” Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg joined other skeptics, {like|